What is it about?
We assessed different approaches to prevent heart attacks and strokes forcost and effectiveness. Amongst these prevention strategies were guideline based strategies that tailor treatment to personal risk and strategies irrespective of risk taking a daily polypill to reduce the risk of heart attacks and strokes starting from different ages.
Featured Image
Why is it important?
We found that period risk assessment using lower risk thresholds as recommended in recent guidelines is unlikely to be cost-effective and that the polypill could be cost-effective if drug prices were reduced.
Perspectives
A population approach with the polypill is currently too costly to be implemented in the UK, but would become cost-effective if drug prices were reduced.
Professor Steffen E Petersen
Queen Mary University of London
Read the Original
This page is a summary of: Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease, Heart, January 2017, BMJ,
DOI: 10.1136/heartjnl-2016-310529.
You can read the full text:
Contributors
The following have contributed to this page
